News
CMMB
0.7698
+1.29%
0.0098
Weekly Report: what happened at CMMB last week (0401-0405)?
Weekly Report · 5d ago
Weekly Report: what happened at CMMB last week (0325-0329)?
Weekly Report · 04/01 11:28
Weekly Report: what happened at CMMB last week (0318-0322)?
Weekly Report · 03/25 11:31
Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab's CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis. The European Patent Office has granted a new patent for the drug. Chemomab is developing a first-in-class antibody that neutralizes CCL24.
Benzinga · 03/25 11:09
Weekly Report: what happened at CMMB last week (0311-0315)?
Weekly Report · 03/18 11:29
Weekly Report: what happened at CMMB last week (0304-0308)?
Weekly Report · 03/11 11:25
Chemomab Therapeutics Is Maintained at Perform by Oppenheimer
Dow Jones · 03/08 13:55
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
Chemomab Therapeutics reported earnings per share of -26 cents for the first quarter. The company did not report any revenue for the quarter. Chemomab did not have any shares of the company to sell on the market at the end of the quarter .
Investorplace · 03/07 17:53
Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01
Seeking Alpha · 03/07 12:55
Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY
Benzinga · 03/07 12:06
Earnings Scheduled For March 7, 2024
CI&T is expected to report quarterly earnings at $0.06 per share on revenue of $106.08 million. Other companies expected to release earnings before the bell include Burlington Stores, American Eagle Outfitters and Bilibili. The companies will also be reporting earnings for their third quarter.
Benzinga · 03/07 09:49
Weekly Report: what happened at CMMB last week (0226-0301)?
Weekly Report · 03/04 11:28
Weekly Report: what happened at CMMB last week (0219-0223)?
Weekly Report · 02/26 11:43
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Agile Therapeutics (NASDAQ:AGRX) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's Q4 earnings came out today. Venus Concept stock rose 72.95% and Indivior shares increased by 16.74%.
Benzinga · 02/22 13:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Inspire Veterinary (NASDAQ:IVP) stock increased by 47.8% to $0.2 during Wednesday's pre-market session. Motus GI Hldgs shares rose 47.17% during the day. Talphera stock rose 18.39% and Ocugen increased by 15.38% in the pre- market session. Losers Avinger and Teladoc Health were among the companies that lost ground.
Benzinga · 02/21 13:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Motus GI Hldgs (NASDAQ:MOTS) shares rose 53.3% to $1.0 during Tuesday's after-market session. Acutus Medical's Q4 earnings report came out today. Clearside Biomedical shares rose 12.39% and NeoGenomics stock increased by 11.42%. Losers Community Health Sys (NYSE:CYH) shares decreased by 14.9% and Avinger shares fell 13.6%.
Benzinga · 02/20 21:31
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
Chemomab Therapeutics Ltd (NASDAQ:CMMB) shares are down 3.33% in Tuesday's trading. The company announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101. The antibody is being assessed in the global Phase 2 trial for primary sclerosing cholangitis.
Benzinga · 02/20 17:30
Weekly Report: what happened at CMMB last week (0212-0216)?
Weekly Report · 02/19 11:46
Weekly Report: what happened at CMMB last week (0205-0209)?
Weekly Report · 02/12 11:33
Weekly Report: what happened at CMMB last week (0129-0202)?
Weekly Report · 02/05 11:44
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.